Zhitong Finance App News, Nuocheng Jianhua (09969.HK) announced that the phase III registered clinical trial of the potent highly selective tyrosine kinase 2 (TYK2) allosteric inhibitor fadeucravacitinib (ICP-488) for the treatment of patients with moderate to severe plaque psoriasis successfully reached its main end.

Zhitongcaijing · 3d ago
Zhitong Finance App News, Nuocheng Jianhua (09969.HK) announced that the phase III registered clinical trial of the potent highly selective tyrosine kinase 2 (TYK2) allosteric inhibitor fadeucravacitinib (ICP-488) for the treatment of patients with moderate to severe plaque psoriasis successfully reached its main end.